NASDAQ : INTS
Intensity Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 3.34 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 10.90M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 5.40M | 5.19M | 6.09M | 3.53M | 2.42M | 2.16M |
| Research & Development | 6.08M | 6.79M | 10.50M | 4.79M | 5.13M | 5.86M |
| Operating Expenses | 11.48M | 11.97M | 16.59M | 8.32M | 7.55M | 8.01M |
| Operating Income | -11.48M | -11.97M | -16.59M | -8.32M | -7.55M | -8.01M |
| Interest Expense | -305.00K | -82.00K | ||||
| Interest & Investment Income | 318.00K | 180.00K | 314.00K | 324.00K | 2.00K | 2.61K |
| Other Non Operating Income (Expenses) | 2.00K | 186.00K | 3.00K | 24.00K | 48.00K | 115.51K |
| EBT Excluding Unusual Items | -11.16M | -11.61M | -16.27M | -8.28M | -7.58M | -7.90M |
| Other Unusual Items | -2.26M | |||||
| Pretax Income | -11.16M | -11.61M | -16.27M | -10.54M | -7.58M | -7.90M |
| Net Income | -11.16M | -11.61M | -16.27M | -10.54M | -7.58M | -7.90M |
| Preferred Dividends & Other Adjustments | 1.32M | |||||
| Net Income to Common | -11.16M | -11.61M | -16.27M | -11.86M | -7.58M | -7.90M |
| Shares Outstanding (Basic) | 2.33M | 1.36M | 556.28K | 344.65K | 136.40K | 136.40K |
| Shares Outstanding (Diluted) | 2.33M | 1.36M | 556.28K | 344.65K | 136.40K | 136.40K |
| EPS (Basic) | -4.80 | -8.56 | -29.24 | -34.42 | -55.58 | -57.88 |
| EPS (Diluted) | -4.80 | -8.56 | -29.24 | -34.42 | -55.58 | -57.88 |
| EBIT | -11.48M | -11.97M | -16.59M | -8.32M | -7.55M | -8.01M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 9.53M | 11.92M | 2.59M | 8.56M | 1.31M | 4.54M |
| Short-Term Investments | 6.22M | |||||
| Cash & Short-Term Investments | 9.53M | 11.92M | 2.59M | 14.78M | 1.31M | 4.54M |
| Other Receivables | 51.26K | |||||
| Receivables | 51.26K | |||||
| Prepaid Expenses | 1.70M | 788.00K | 773.00K | 688.00K | 63.00K | 70.44K |
| Other Current Assets | 76.00K | 69.28K | ||||
| Total Current Assets | 11.23M | 12.71M | 3.36M | 15.46M | 1.45M | 4.73M |
| Property, Plant & Equipment | 82.00K | 96.00K | 122.00K | 147.00K | 139.00K | 318.13K |
| Other Long-Term Assets | 210.00K | 1.30M | 1.30M | 1.68M | 167.00K | 167.74K |
| Total Assets | 11.52M | 14.10M | 4.78M | 17.30M | 1.76M | 5.22M |
| Accounts Payable | 1.01M | 583.00K | 1.22M | 3.05M | 603.00K | 172.51K |
| Accrued Expenses | 1.20M | 1.53M | 508.00K | 891.00K | 331.00K | 335.24K |
| Short-Term Debt | 4.35M | 2.02M | ||||
| Current Portion of Leases | 33.00K | 31.00K | 28.00K | 20.00K | 143.00K | 182.34K |
| Other Current Liabilities | 1.39M | 1.01M | ||||
| Total Current Liabilities | 2.25M | 2.15M | 1.75M | 3.96M | 6.82M | 3.72M |
| Long-Term Leases | 62.00K | 79.00K | 110.00K | 138.00K | 143.57K | |
| Other Long-Term Liabilities | 36.00K | 36.00K | 36.00K | |||
| Total Liabilities | 2.31M | 2.23M | 1.86M | 4.13M | 6.86M | 3.90M |
| Common Stock | 1.00K | 341.00 | ||||
| Additional Paid-In Capital | 93.04M | 90.27M | 69.70M | 63.68M | 23.55M | 22.39M |
| Retained Earnings | -83.83M | -78.39M | -66.78M | -50.52M | -38.65M | -31.07M |
| Total Common Equity | 9.21M | 11.88M | 2.92M | 13.16M | -15.10M | -8.68M |
| Shareholders' Equity | 9.21M | 11.88M | 2.92M | 13.16M | -5.10M | 1.32M |
| Total Liabilities & Equity | 11.52M | 14.10M | 4.78M | 17.30M | 1.76M | 5.22M |
| Total Debt | 95.00K | 110.00K | 138.00K | 158.00K | 4.49M | 2.34M |
| Net Cash (Debt) | 9.43M | 11.81M | 2.45M | 14.62M | -3.18M | 2.20M |
| Net Cash Per Share | 4.06 | 8.71 | 4.41 | 42.41 | -23.31 | 16.10 |
| Filing Date Shares Outstanding | 3.26M | 2.54M | 607.24K | 548.38K | 136.40K | 136.40K |
| Total Common Shares Outstanding | 2.95M | 2.52M | 604.91K | 548.38K | 136.40K | 136.40K |
| Working Capital | 8.98M | 10.56M | 1.61M | 11.51M | -5.37M | 1.01M |
| Book Value Per Share | 3.13 | 4.70 | 4.82 | 24.00 | -110.69 | -63.67 |
| Tangible Book Value | 9.21M | 11.88M | 2.92M | 13.16M | -15.10M | -8.68M |
| Tangible Book Value Per Share | 3.13 | 4.70 | 4.82 | 24.00 | -110.69 | -63.67 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -11.16M | -11.61M | -16.27M | -10.54M | -7.58M | -7.90M |
| Other Amortization | 159.00K | |||||
| Asset Writedown & Restructuring Costs | 27.00K | 26.00K | 25.00K | 147.00K | 179.00K | 172.11K |
| Stock-Based Compensation | 1.70M | 2.00M | 3.12M | 1.40M | 1.17M | 719.82K |
| Other Operating Activities | 2.26M | |||||
| Change in Accounts Payable | 279.00K | 360.00K | -2.27M | 1.63M | 704.00K | -50.20K |
| Change in Other Net Operating Assets | 208.00K | -13.00K | 167.00K | -2.26M | 53.00K | 227.00K |
| Operating Cash Flow | -8.95M | -9.23M | -15.22M | -7.21M | -5.48M | -6.83M |
| Investment in Securities | 6.35M | -6.02M | ||||
| Investing Cash Flow | 6.35M | -6.02M | ||||
| Short-Term Debt Issued | 230.00K | 2.25M | 2.00M | |||
| Total Debt Issued | 230.00K | 2.25M | 2.00M | |||
| Net Debt Issued (Repaid) | 230.00K | 2.25M | 2.00M | |||
| Issuance of Common Stock | 17.20M | 20.38M | 3.55M | 22.48M | 50.00K | |
| Other Financing Activities | -933.00K | -1.82M | -653.00K | -2.23M | ||
| Financing Cash Flow | 16.27M | 18.56M | 2.90M | 20.47M | 2.25M | 2.05M |
| Net Cash Flow | 7.31M | 9.33M | -5.97M | 7.24M | -3.23M | -4.78M |
| Levered Free Cash Flow | -6.28M | -5.11M | -9.54M | -2.77M | -2.74M | -3.97M |
| Unlevered Free Cash Flow | -6.28M | -5.11M | -9.54M | -2.74M | -2.69M | -3.97M |
| Change in Working Capital | 487.00K | 347.00K | -2.10M | -633.00K | 757.00K | 176.80K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 11.10M | 24.64M | 26.58M | 117.49M | ||
| Enterprise Value | 1.67M | 17.69M | 23.95M | 102.00M | ||
| Last Close Price | 3.40 | 10.26 | 44.00 | 214.25 | ||
| PB Ratio | 1.09 | 2.08 | 9.11 | 8.93 | ||
| P/TBV Ratio | 1.20 | 2.08 | 9.11 | 8.93 | ||
| Debt / Equity Ratio | 0.01 | 0.01 | 0.05 | 0.01 | -0.88 | 1.78 |
| Net Debt / Equity Ratio | -1.02 | -0.99 | -0.84 | -1.11 | -0.62 | -1.67 |
| Quick Ratio | 4.25 | 5.55 | 1.48 | 3.73 | 0.19 | 1.23 |
| Current Ratio | 5.00 | 5.92 | 1.92 | 3.91 | 0.21 | 1.27 |
| Return on Equity (ROE) | -195.88% | -156.90% | -202.34% | -261.36% | -161.84% | |
| Return on Assets (ROA) | -89.91% | -79.25% | -93.90% | -54.58% | -135.34% | -65.19% |
| Return on Capital Employed (ROCE) | -123.80% | -100.10% | -547.70% | -62.40% | 149.20% | -535.90% |
| Earnings Yield | -141.15% | -47.11% | -61.19% | -8.97% | ||
| Buyback Yield / Dilution | -273.56% | -143.83% | -61.40% | -152.67% | -0.02% |